AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KOCT 282 min read$AMRN

Amarin Reports 2026 Third Quarter Financial Results, Achieves Positive Net Income

AMARIN CORP PLC\UK (AMRN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Amarin Reports 2026 Third Quarter Financial Results, Achieves Positive Net Income DUBLIN, Ireland and BRIDGEWATER, N.J., October 28, 2026 -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today

Original reporting
SEC EDGAR 8-K
Published Oct 28, 2026, 11:05 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 11:09 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$AMRN
Neutral
high confidence
Mentioned
$AMRN
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$AMRNNeutralMed
01

Why it matters

The earnings release provides fresh data on revenue trends, expense reductions, and market share, offering traders new information to reassess valuation.

02

Market read

First‑time profit after losses and a notable revenue decline provide mixed signals for investors, making the release a moderate‑impact earnings event.

03

What to watch

Future earnings may be volatile due to dependence on partner inventory levels and pricing pressures in the U.S. market.

Relevance 7/10Novelty 7/10Timing: after-hours release

Background

Amarin Corp PLC (NASDAQ: AMRN) announced its Q3 2026 financial results, marking its first profitable quarter in over two years.

Company-level read

Ticker impact

$AMRNNeutralHigh confidence
Context

Amarin Corp PLC filed an 8‑K reporting Q3 2026 results with a surprise profit and a 20% revenue decline.

Expected impact

modest upside as profit surprise may attract short covering, but revenue decline could limit gains

Evidence & confidence

The unexpected net profit after two years of losses is positive, yet a 20% drop in revenue and lower U.S. sales may temper enthusiasm.

Market effects

Sector

Highlights ongoing pressure in the cardiovascular drug market and the impact of generic competition on IPE products.

Regional

Shows strong European demand growth via Recordati partnership, potentially boosting regional biotech sentiment.

Global

Demonstrates the effect of partner-led sales models on global pharma revenue trends.

Counterpoint

What could challenge this read

Despite profit, the steep revenue decline and reliance on partner sales could signal longer‑term challenges.

Key entities

  • company
    Amarin Corp PLC

    Pharmaceutical company focused on cardiovascular disease treatments.

  • partner
    Recordati S.p.A.

    Exclusive licensee and distributor for Amarin's VASCEPA/VAZKEPA in Europe.

Read at source← All news

Related articles

OCT 25
$AMRNMedAI 8/10

Amarin’s icosapent ethyl shows survival benefit in cancer trial

Amarin Corporation (NASDAQ:AMRN) reported Phase 3 trial results for icosapent ethyl in colorectal cancer liver metastases. The primary endpoint of progression-free survival was not met, but the key secondary endpoint of overall survival showed a statistically significant benefit. The five-year overall survival estimate was 62.0% with icosapent ethyl versus 45.1% with placebo. The drug was found to be safe and well tolerated.

investing.com2 min
OCT 25
$AMRNMedAI 8/10

A colorectal cancer trial missed its goal, but estimated 5-year survival was 62% with the drug versus 45% with placebo.

Amarin's drug VASCEPA failed to meet its primary endpoint in a colorectal cancer trial but showed a 5-year survival rate of 62% vs. 45% with placebo. The study, sponsored by the University of Leeds, found improved overall survival but not progression-free survival. Amarin plans further evaluation, citing potential long-term value.

stocktitan.net2 min
AUG 8
$AMRNMed

Amarin (AMRN) Q2 2026 Earnings Call Transcript

Amarin (AMRN) reported Q2 2026 results on an earnings call. Total net revenue was $42.2M, down 42% year over year, mainly due to a $25M upfront licensing payment in 2025. U.S. product revenue fell to $32.2M, while Europe product revenue rose to $5.4M. Operating loss narrowed to $12.0M and cash and investments were $314.6M.

fool.com7 min
JUL 29
$AMRNMed

Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading…

AMARIN CORP PLC\UK (AMRN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence Q2 2026 Results Highlight Global Volume Growth, Lower Operating Expenses and Positive Cash

SEC EDGAR 8-K6 min